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Abstract
Purpose The frequent occurrence of ventricular tachycardia
can create a serious problem in patients with an implantable
cardioverter defibrillator. We assessed the long-term effica-
cy of catheter-based substrate modification using the
voltage mapping technique of infarct-related ventricular
tachycardia and recurrent device therapy.
Methods The study population consisted of 27 consecutive
patients (age 68±8 years, 25 men, mean left ventricular
ejection fraction 31±9%) with an old myocardial infarction
and multiple and/or hemodynamically not tolerated ventricu-
lar tachycardia necessitating repeated device therapy. A total
of31substratemodificationprocedureswereperformedusing
the three-dimensional electroanatomical mapping system.
Patients were followed up for a median of 23.5 (interquartile
range 6.5–53.2) months before and 37.8 (interquartile range
11.7–71.8) months after ablation. Antiarrhythmic drugs were
not changed after the procedure, and were stopped 6 to
9 months after the procedure in patients who did not show
ventricular tachycardia recurrence.
Results Median ventricular tachycardias were 1.6 (inter-
quartile range 0.7–6.7) per month before and 0.2 (inter-
quartile range 0.00–1.3) per month after ablation (P=
0.006). Nine ventricular fibrillation episodes were regis-
tered in seven patients before and two after ablation (P=
0.025). Median antitachycardia pacing decreased from 1.6
(interquartile range 0.01–5.5) per month before to 0.18
(interquartile range 0.00–1.6) per month after ablation (P=
0.069). Median number of shocks decreased from 0.19
(interquartile range 0.04–0.81) per month before to 0.00
(interquartile range 0.00–0.09) per month after ablation (P=
0.001). One patient had a transient ischemic attack during
the procedure, and another developed pericarditis. Nine
patients died during follow-up, eight patients due to heart
failure and one patient during valve surgery.
Conclusion Catheter-based substrate modification using
voltage mapping results in a long-lasting reduction of
cardioverter defibrillator therapy in patients with multiple
and/or hemodynamically not tolerated infarct-related ven-
tricular tachyarrhythmia.
Keywords Ablation.Substrate modification.
Tachyarrhythmia.Follow-up studies.Ventricular
tachycardia
1 Introduction
Implantable cardioverter defibrillator (ICD) devices have
improved prognosis in patients with low left ventricular
ejection fraction (LVEF) and ventricular tachyarrhythmia.
However, these devices are not capable of preventing
recurrences of ventricular tachycardia (VT) appearing in
up to 70% of patients. In 3% to 5% of patients, electrical
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DOI 10.1007/s10840-011-9549-1storm occurs, often many years after infarction [1]. ICD
shocks are painful, and repeated appropriate ICD shocks are
an increasing clinical problem requiring hospital admission
and are accompanied by anxiety and depression in more
than 50% of patients [2–4]. ICD shocks require high
voltage, and frequent shocks lead to premature depletion
of the ICD battery and early device replacement. VT is the
most common cause of appropriate ICD shocks. In the
infarcted human heart, VTs usually arise in the subendo-
cardial region using slowly conducting narrow bundles
(smallest width 250 μm) of viable myocardium in and
around the infarcted area [5–8]. Such a conducting channel
differs from the surrounding scar tissue by a higher voltage
[9]. As described by Arenal et al., a channel is called
complete when it is surrounded by two scar areas, or one
scar area and the mitral annulus and is connected to normal
myocardium at least at two sites [10]. Incomplete channels
are connected to normal myocardium at only one site [10].
The presence of multiple morphologies and/or hemody-
namically intolerant VTs has limited the widespread
applicability of conventional catheter ablation therapy [11,
12]. The voltage mapping approach during sinus rhythm is
an effective approach to identify and ablate the slow
conduction channels with an acute procedural success of
about 75% [13–15]. We report the long-term (median
follow up of 3 years) results of our population who
underwent this procedure.
2 Methods
2.1 Study population
From a group of 190 patients who underwent radio-
frequency catheter ablation (RFCA) for VT at the academic
hospital of Maastricht between November 2000 and
December 2007, 86 patients had ischemic ventricular
tachycardia. Our study population consisted of a subgroup
of 27 consecutive patients who underwent substrate
modification and RFCA using the voltage mapping tech-
nique and who had an ICD implanted. This strategy was
prospectively decided because of unmappable VT(s).
Although VT induction protocol was used in all patients
at the beginning of each procedure, no mapping during VT
was performed. Unmappable VT was defined as being
hemodynamically unstable and/or having multiple clinical
VT morphologies. Four of our patients had an incessant VT
which changes morphologies. Incessant VT was defined as
a VT that persists for more than half of a 24-h period.
Seventeen patients had an electrical storm, defined as ≥3
distinct arrhythmic episodes (VT/VF) in 24 h usually
requiring electrical cardioversion or defibrillation [16].
The mean age of the patients was 68±8 years, and all but
two were men. The scar from the myocardial infarction was
located: anterior in 12, inferior in 10, posterior in 3, and
inferoposterolateral in 2 patients. The mean time interval
from infarction to catheter ablation was 21±8 years. The
mean LVEF was 31±9%. Most patients were on a
combination of amiodarone and a beta-blocker (19
patients). Six patients had only beta-blockers, one patient
was on amiodarone alone, and one patient on sotalol alone
(Table 1). VTs were documented by a 12-lead ECG. A
sustained VT episode was clinically defined as a VT lasting
more than 30 s. All patients had an ICD during follow-up:
23 patients before the procedure (median 23.5 (interquartile
range (IQR) 6.5–53.2) months) and 4 patients within a few
days after the procedure. From the four patients in whom
no ICD was implanted before the procedure, information of
the VT episodes was obtained from the clinical chart, and
thus underestimated. The ICD definition of sustained VT
episode varies from 8 to 30 consecutive ventricular beats,
depending on the ICD manufacturer and programming.
AADs were not changed directly after the procedure. The
beta-blockers and the sotalol were continued during the
study (ischemic heart disease, concomitant paroxysmal
atrial fibrillation). The amiodarone was stopped 6 to
9 months after the index procedure in the nine patients
who did not had VT recurrences and 6 to 9 months after the
second procedure in the two patients who did not had VT
recurrences. AADs were not changed in the rest of the
patients.
2.2 Electrophysiological study, mapping, and ablation
technique
Patients were studied in a fasting state. During left
ventricular (LV) mapping and ablation, heparin was
administered to achieve and maintain an activated coagu-
lation time >250 s, and the ICD was deactivated. Three 6F
quadripolar electrode catheters were advanced via the
femoral vein to the high right atrium, His-bundle region,
and right ventricular (RV) apex. All patients had a
documented 12-lead ECG of the clinical VT(s). Patients
underwent programmed electrical stimulation with up to
three extrastimuli, using three different cycle lengths
(600–500–430 ms). Pacing was performed only from the
RV apex. All patients had at least one unmappable VT.
Electroanatomical substrate mapping with the CARTO™
system (Biosense-Webster Inc., Diamond Bar, CA) was
performed using the retrograde aortic approach via the
femoral artery during sinus rhythm (30 procedures) or
RV pacing (1 procedure). Sequential point-by-point
acquisition was done to build the LV geometry. Endo-
cardial electrograms were analyzed and categorized
according to the presence of late potentials and frag-
mented electrograms. Sites with an electrogram ampli-
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<0.5 mV as densely scarred endocardium [17], and values
in between as the border zone of the infarction. Analysis
of the voltage map, the clinical VT(s) morphology and the
endocardial electrograms were performed to identify
candidate regions of slow conduction responsible for the
VT(s). Pace mapping was used to target the site of ablation
in the majority of patients (Fig. 1). Ablation was
performed using a conventional 4-mm tip RF ablation
catheter (Cordis-Webster). If pace mapping produced 12-
lead QRS morphology similar to the targeted VT, a linear
ablation lesion was made from the exit point parallel to the
scar margin, from the exit point to the densely scarred
myocardium or from a densely scarred myocardium to the
mitral valve annulus (three patients). Reentry circuit
isthmus was identified in five patients and was defined
on the basis of the results of pace mapping as a site where
the QRS morphology matched that of VT with a pacing
stimulus-QRS interval of ≥40 ms [18, 19]. When the
isthmus was identified, a linear lesion was made crossing
the isthmus connecting two densely scarred areas. RF
current was applied for 90 s; temperature and power were
l i m i t e dt o6 0 –70°C and 50 W, respectively. Saline-
irrigated tip (SIT) catheter (The Thermo-Cool™ catheter,
Cordis-Webster) was used seven times during the index
procedure and two times during the second procedure. The
Table 1 Patient characteristics
Patient no. Age Sex MI EF % Time from
MI (years)
AAD Before ablation
No. of VT
episodes
Morphology of
clinical VT(s)
No. of
inducible VTs
VT cycle length
range (ms)
1
a 76 m I 48 25 Class III, BB 15 LB-LA(×2), RB-RA 3 330–360
2
a 73 f P 45 26 Class III, BB 15 RB-LA, LB-LA(×3) 5 330–420
3 81 m A 26 37 Class III, BB Incessant (storm) RB-NW, RB-LA 2 320–400
4 71 m I 30 12 Class III, BB 82 (storm) RB-LA, LB-IA 2 300–310
5 69 m I 33 19 Class III, BB 87 (storm) RB-LA 1 270
6
a 45 m A 30 14 Class III 5 RB-LA 2 220–300
7 75 m A 25 17 Class III, BB 43 (storm) RB-LA 5 220–370
8 79 m IPL 35 16 Class III, BB 92 (storm) RB-NW, LB-LA 2 340–400
9 62 m A 36 21 Class III, BB 616 (storm) LB-RA 1 270
10
a 70 m I 19 24 Class III, BB Incessant (storm) RB-RA 2 300–340
11 60 m P 38 NA Class III, BB 132 (storm) RB-LA 1 300
12 62 m I 30 17 BB 17 RB-NW 1 280
13
a 54 m A 28 24 Class III, BB 170 (storm) RB-NW 5 330–480
14
a 58 m A 30 14 Class III, BB 15 RB-LA 2 320–370
15 77 m A 35 23 Class III, BB 10 RB-LA(×2) 2 330–340
16
a 60 m A 25 12 BB 20 RB-NW, RB-RA 2 320–470
17 67 m P 30 24 Class III, BB Incessant (storm) RB-NW, RB-RA 2 250–410
18 62 m I 50 24 Class III 15 RB-RA, RB-LA 2 480–520
19 70 m A 35 22 BB 58 (storm) RB-RA (×2) 2 300–500
20 68 m IPL 20 19 Class III, BB Incessant (storm) RB-NW, RB-RA 2 250–600
21 73 f A 25 40 BB 4 RB-RA, RB-LA 3 290–320
22
a 69 m I 45 7 BB 221 (storm) RB-LA 1 330
23
a 74 m A 24 30 BB 76 (storm) RB-LA (×2) 3 250–390
24 81 m I 20 28 Class III, BB 37 LB-LA, RB-RA 2 470–510
25 76 m A 22 11 Class-III, BB 2,979 (storm) LB-LA&RA,RB-RA 3 360–550
26 75 m I 21 26 Class-III, BB 59 (storm) RB-NW (×2) 4 450–660
27 63 m I 30 20 Class-III, BB 51 (storm) RB-LA, RB-NW 5 250–230
A anterior wall MI, AAD antiarrhythmic drugs, BB beta-blockers, Class-III class III antiarrhythmic drugs, EF ejection fraction, f female, I inferior
wall MI, IA intermediate axis, IPL inferoposterolateral MI, LA left axis, LB left bundle branch block morphology, M male, MI myocardial
infarction, NW northwest axis, RA right axis, RB right bundle branch block morphology, storm, VT electrical storm, VT ventricular tachycardia,
×2, ×3, indicates 2 or 3 different VT morphologies with the same bundle branch block and axis
aPatients in which irrigated tip catheter were used
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the target power set at 30 W and increased to 50 W when
required. Temperature cutoff was programmed at 50°C.
RF pulse was delivered for 90 s. Continuous saline flow
was maintained at 2 mL/min and increased to 30 mL/min
during RF delivery. Both clinical VT(s) and the
preablation-induced VT(s) were targeted. Programmed
stimulation with up to three extrastimuli using three
different cycle lengths (600–500–430 ms) at one site (RV
apex) was repeated to determine procedural success. Acute
success was defined as the inability to reinduce both the
clinical and the induced VT(s) before ablation.
2.3 Follow-up
Patients were followed up every 3 months in our ICD
outpatient clinic. During these visits, the ICD was interro-
gated, and arrhythmic events and device therapy were
analyzed. Interrogation intervals were shorter when clini-
cally indicated. Not all VT episodes require therapy, and
one VT episode may require more than one therapy,
depending on the ICD programming. A 12-lead ECG was
made in the cases in which the arrhythmia occurred in-
hospital, in all other cases recordings were obtained from
the device memory.
2.4 Statistical analysis
Statistical analysis was performed using the SPSS software
package version 15.0.0 (SPSS Inc, 2006). Variables are
expressed as mean ± standard deviation (SD) or median
with interquartile range (IQR) when not normally distrib-
uted. Mean values were compared using the Student's t test
for paired data and median values using the Wilcoxon
signed-rank test. Kaplan–Meier curve was used to calculate
the cumulative probability of the remaining free from
appropriate ICD shocks. Statistical significance was estab-
lished at P<0.05.
3 Results
3.1 Acute results
A total of 67 different VTs were induced in the 27 patients
studied during the index procedure (2.5±1.3 VTs/patient).
A single VT morphology was induced in five patients. In
patients with an anterior wall myocardial infarction, the
number of inducible VTs was 2.6±1.2, and 1.3±0.7 in
patients with an inferior wall infarction (P=0.03). The
mean VT-cycle length (VTCL) was 363±101 ms. There
Fig. 1 (a) Voltage map during sinus rhythm of the left ventricle in a
posterior–anterior view in a patient with an inferoposterolateral
infarction. The patient had two different VTs: VT1 with left bundle
branch block morphology and left axis, and VT2 with right bundle
branch block morphology and northwest axis. Color range indicates
the electrogram amplitude. Purple represents normal myocardium
(>1.5 mV); gray, dense scar (<0.5 mV); and range between purple
and red, border zone (0.5–1.5 mV). The 12-lead ECG during VT and
pace mapping (b), (c) directed the linear ablation. Arrows indicate the
site where the exit point of the VTs was found. Linear lesions (red
dark dots) were extended from dense scar and across the border zone
152 J Interv Card Electrophysiol (2011) 31:149–156was no significant difference between the VTCL in patients
with anterior (345±85 ms) versus inferior wall myocardial
infarction (365±112 ms; P=0.13). The mean scar diameter
was 66±22×53±25 mm (area 40±24 cm
2). The mean
number of RF applications was 13±7. All clinical and
preablation inducible VTs were targeted and successfully
ablated. There was no inducible VT after ablation in 21
patients. In the remaining six patients, eight VTs were
induced (two patients had inducible polymorphic VT/VF
and four patients had six inducible monomorphic VT(s) not
matching the morphology or cycle length of the clinical or
the preablation VT(s); these VT(s) were not targeted for
ablation).
3.2 Duration of the procedure, fluoroscopy exposure,
and complications
The mean procedure time was 290±92 min, and the mean
fluoroscopy time was 56±16 min. One patient had a
transient ischemic attack during the procedure, and another
developed a self-limiting pericarditis.
3.3 Long-term follow-up
A total of 31 VT ablation procedures were performed in 27
patients. After the index procedure, 23 patients (85%) did
not require a second ablation procedure. In four patients
(15%), a second procedure was necessary due to recurrence
of multiple hemodynamically not tolerated VT(s) and
repeated device therapies (three patients within 7 months
and one patient after 4 years). Patients were followed up for
a median of 23.5 (IQR 6.5–53.2) months before and
37.8 months (IQR 11.7–71.8) after the index procedure.
Seven thousand seven hundred thirty-six episodes of VT
were registered, 5,203 before and 2,533 after the procedure.
Nine patients (33%) remained completely free of VT after
the index ablation (Fig. 2). The median number of VTs was
1.6 per month (IQR 0.7–6.7) before and 0.2 per month
(IQR 0.00–1.3) after the index ablation, (P=0.006). The
mean recurrent VTCL was 531±98 ms which was longer
than the VTCL (363±101 ms) before catheter ablation (P=
0.0001). Nine VF episodes were registered in seven patients
before and two after the index ablation (P=0.025). A total
of 9,251 antitachycardia pacing (ATP) episodes were
registered during the study, 6,036 before and 3,212 after
the procedure. Median ATP decreased from 1.6 (IQR 0.01–
5.5) per month before to 0.18 (IQR 0.00–1.6) per month
after the index ablation (P=0.069). Five hundred sixteen
appropriate shocks were registered during the study, 409
before and 107 after the index ablation. Fourteen patients
(52%) remained free of ICD shocks after the index ablation
(Fig. 3). Median number of shocks decreased from 0.19 per
month (IQR 0.04–0.81) before to 0.00 per month (IQR
0.00–0.09) after the index ablation (P=0.001). Of all
patients, 63% (17/27) experienced at least 75% reduction
in their monthly ICD interventions (ATP and shocks) after
the index procedure. The probabilities of surviving free
from any ICD shock after catheter ablation were 64%, 52%,
and 46% after 10, 20, and 50 months of follow-up,
respectively (Fig. 4). The mean number of shocks was 7.2
per patient in the 3 months prior to catheter ablation,
decreased to 0.7 shocks per patient in the 3 months after
ablation and 0.2 shocks per patient per 3 months during the
third year of follow-up. Irrigated tip catheter was used in
seven patients during the index ablation procedure. Four of
these patients remained free from any VT after the
procedure (Figs. 2 and 3). From the 27 patients, four
required a second catheter ablation procedure due to
recurrence of hemodynamically not tolerated VTs and
increased device therapy. Irrigated tip catheter was used in
2. After the second ablation, all four patients remained free
of appropriate ICD shocks, and two of them remained free
from VTs (Figs. 2 and 3). After the second procedure, 78%
of all patients (21/27) had at least 75% reduction in their
27 patients 
VT
* 5203, ATP
* 6036 
(F/U
* 23.5 months)
9 patients (4) 
Before: VT 1307, ATP 1356 
After: no VT, no ATP 
(F/U 12.7 months)  
Index procedure (7) 
14 patients (3) 
Before: VT 3718, ATP 4458 
After:VT 2275, ATP 2796 
(F/U 42.8 months) 
2 pts. (1): no VT, no ATP 
2 pts. (1): VT 7, ATP 8  
(F/U 15.4 months) 
2
nd procedure (2)
4 patients  
251 VT, 411 ATP (F/U 6.8  months) 
Fig. 2 Diagram showing the total
number of VTs and ATPs and the
median follow-up period before
and after substrate modification.
Patients were divided according to
VT recurrences. After the index
procedure, nine patients were to-
tally VT free. Four patients had
recurrences requiring a second
ablation procedure, and 14 patients
had recurrences without the clini-
cal necessity for a second ablation
procedure. *ATP antitachycardia
pacing, F/U median follow-up
period, VT ventricular tachycardia
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follow-up period, eight patients died due to heart failure
and one patient during valve surgery.
4 Discussion
4.1 Main findings
To our knowledge, this is the first study reporting the long-
term follow-up (37.8 months (IQR 11.7–71.8)) after
substrate modification of unmappable VTs. In this study,
the recurrence of VTs was continuously monitored with an
ICD device. It reveals a significant long-lasting reduction of
VTs with a clinically relevant reduction of ICD therapy
after substrate modification in patients who had suffered
from frequent ICD shocks. Eighty-five percent of patients
were clinically stable with no necessity for a second
procedure. After an acute procedural success of 100%,
33% of patients remained completely free from VT during
follow-up. In case of VT recurrence, the VTs were
significantly slower and less persistent. The number of
ATPs per VT before (6,036 ATP to 5,203 VT≈1.2) is
almost the same as after the index procedure (3,212 ATP to
2,533 VT≈1.3). In the mean time, the number of VT
episodes leading to one shock was clearly increased after
ablation (5,203/409≈13 versus 2,533/107≈24). We believe
that the prolongation in VTs' cycle length has made them
better terminable with ATP contributing to a significant
decrease in the number and the frequency of ICD shocks.
Fifty-two percent and 67% of patients remained free from
ICD shocks at the end of the study after the index and the
second ablation procedure, respectively. Although irrigated
tip catheters were only used in nine procedures, it seems
that these catheters are more effective in preventing VT
recurrence [20].
4.2 Previous studies
Long-term results of catheter ablation of unmappable VTs are
unknown. Several studies have been published showing the
short-term procedural results. When voltage mapping and
ablation of the exit point—identified by pace mapping—were
used, 46–93% of patients remained free of VT after a follow-
up of 3 to 8 months [13, 21, 22]. Voltage mapping and
ablation of isthmuses identified by pace mapping (spike
QRS≥40 ms) achieved 33–82% survival free of VTs after 9–
15 months of follow-up [15, 23, 24]. When using fraction-
ated electrograms or electrograms with late potentials as
guide for catheter ablation, 60–80% patients had no recurrent
27 patients 
409 shocks 
(F/U
* 23.5 months)
Index procedure (7)
4 patients 
Before: 110 shocks   
After: 51 shocks (F/U 6.8 months) 
9 patients (2) 
Before: 203 shocks 
After: 56 shocks 
(F/U 43.7 months) 
14 patients (5) 
Before: 96 shocks  
After: no shocks 
(F/U 18.9 months) 
2
nd procedure (2) 
4 patients  
No shocks  
(F/U 15.4 months) 
Fig. 3 Diagram showing the
total number of appropriate ICD
shocks and the median follow-up
period before and after substrate
modification. Patients are divided
according to the occurrence of
ICD shock. After the index pro-
cedure, 14 patients were totally
shock free. Four patients had
multiple shocks requiring a sec-
ond ablation procedure, and nine
patients had ICD shocks without
the clinical necessity for a second
ablation procedure. *F/U median
follow-up period
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Fig. 4 Kaplan–Meier curve shows the probability of survival without
an ICD shock till the 50th month of follow-up
154 J Interv Card Electrophysiol (2011) 31:149–156VT after a follow-up of 9–19 months [25–27]. However,
some of these studies did not evaluate the arrhythmia
occurrence using the continuous monitoring capability of
the ICD [15, 24, 27].
Our results cannot also be compared to the above-
mentioned studies because of the different methodology
used in the identification of the origin of VTs, and because
other VT etiologies were also included [13]. In some
studies, not all patients were mapped during sinus rhythm
[15, 21, 23, 27]. However, when we analyzed only patients
with an ICD and unmappable VTs due to an old myocardial
infarction, one can see that the short-term results were
almost comparable to our study despite having used a
different methodology in modifying the substrate. It is
important to emphasize that ICD interrogation helped to
identify recurrence of VTs. Interestingly, the cycle length of
the recurrent VTs was much longer than the one before the
substrate modification, making them more responsive to
ATP therapies.
4.3 Clinical implications and future perspective
This study, although not randomized, provides useful
information regarding the management of patients with
frequent ICD discharges. Catheter ablation reduced the
frequency and persistency of VT, which is of clinical
importance, because of the reduction of painful experien-
ces, improvement in quality of life, and better long-term
prognosis [28–31]. As shown in different studies [17, 30],
the beneficial effect of catheter ablation in the patient with
frequent ICD interventions is obvious, but an important
question remains unanswered: Should every patient with
VT(s), an old myocardial infarction, and an ICD undergo a
substrate modification using the voltage mapping proce-
dure? A large multicenter trial is needed to confirm whether
catheter ablation improves the prognosis of patients with an
old myocardial infarction, VT, and an ICD.
4.4 Study limitations
This study was a retrospective analysis and not a
randomized trial. The study included a relatively small
number of patients. The slow conduction zone(s) voltage
mapping was done during sinus rhythm in almost all
patients which is less sensitive in detecting late potentials
and fragmented electrograms than voltage mapping during
sinus rhythm combined with RV pacing or RV pacing alone
as previously reported [25, 32]. The central isthmus was
only identified in five patients possibly due to the fact that
we used a cutoff value of <0.5 mV to identify nonconduct-
ing scarred myocardium. Using a voltage map definition
ranging from 0.5 to 0.2 mV might have facilitated isthmus
identification [10].
5 Conclusion
Catheter-based substrate modification using voltage map-
ping results in long-lasting reduction of VT and ICD
discharges in patients with unmappable VT.
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